Background: Biodegradable polymer-coatings have the potential advantage of being metabolized prior to tissue toxicity and drug delivery during a predefined window. In this study we examined whether paclitaxel eluting stent on biodegradable polymer basis can prevent neointima formation in a porcine stent restenosis model. Methods: We placed coronary stents among CCS-Kflex stent (CCSK, bare stent, tubular, balloon-expandable flexible stent made of stainless steel), CCPS-Kflex stent [CCPSK, biodegradable polyactid-polyglycolid (PLGA)-polymer-coated CCSK stent], and BIOTAX stent (the same polymer coated Paclitaxel eluting CCSK) at random in two selected coronary arteries of 12 pigs with the technique of overdilation injury. Quantitative coronary angiogram (QCA) at first and 4 weeks and histologic analysis at 4 weeks after overdilation injury was performed. Results: The BIOTAX stent release 8 mg Paclitaxel in the first 11 days. Four weeks after stenting, QCA showed significant reduction of diameter stenosis (18.3짹8.3 % vs. 27.2짹11.2 % or 39.8짹14.2 %, p=0.038, 0.020, respectively) in the BIOTAX group comapared with CCSK or CCPSK group. In histopathologic analysis, neointimal area (1.7짹1.8 mm2 vs. 4.8짹2.1 mm2 or 5.8짹3.7 mm2, p=0.029, 0.052, respectively) and area stenosis (25.9짹13.6 % vs. 35.6짹11.8 % or 55.6짹17.1 %, p=0.018, 0.010, respectively) were significantly decreased in the BIOXTAX group compared with CCSK or CCPSK group. The laboratory findings before and at 4 weeks after stenting revealed no differences. Conclusion: Paclitaxel eluting stent on the PLGA-polymer basis is safe and effective in preventing neointima formation in a porcine stent restenosis model.